ArticleImmunology2013

The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy.

Carlos Peinado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.